Compare BAFN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BAFN | RFL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 61.1M |
| IPO Year | 2021 | 2017 |
| Metric | BAFN | RFL |
|---|---|---|
| Price | $6.59 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 58.8K |
| Earning Date | 04-30-2026 | 03-30-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 133.93 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $5.72 | $1.12 |
| 52 Week High | $19.15 | $3.19 |
| Indicator | BAFN | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 76.62 |
| Support Level | $6.31 | $1.41 |
| Resistance Level | $8.26 | $1.60 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 6.34 | 75.61 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.